International Menopause Society Calls Upon Medical Community to Improve the Vaginal Health of Postmenopausal Women

London (ots/PRNewswire) - To mark World Menopause Day
on 18th October 2010, the International Menopause Society (IMS) is
launching new Recommendations for the management of postmenopausal
vaginal atrophy, a distressing condition that will affect up to half
of women after menopause.[1] This new guidance is essential as,
according to new research, one in two women with vaginal atrophy (VA)
will live with their condition unnecessarily for over three years,
despite effective treatments being available. The data suggests that
this is largely due to poor awareness and understanding of the
condition among women, and because VA is a "taboo" subject - even
between a doctor and patient.

VA is characterised by symptoms including vaginal dryness,
itching, increased tendency of infection and pain during sex. It
occurs when the vaginal walls become thin, fragile and inflamed due
to a reduction of oestrogen in the body.[2] While VA has an obvious
impact on sexual intimacy, it also has negative consequences for a
woman's personal relationships, self-esteem and overall quality of
life. If left untreated, VA can lead to serious long-term urogenital
problems, including incontinence.[3] However, despite these negative
implications, just one in four women will actually speak to her
doctor about VA.1

Dr David Sturdee, President of the IMS and lead author of the
Recommendations, said, "It is unacceptable that women are living with
VA for so long, when various safe and effective treatments are
available. So, to mark World Menopause Day, the IMS is launching the
new Recommendations and is calling upon doctors to proactively raise
the topic of vaginal health with postmenopausal patients. Women with
VA are also encouraged to seek medical advice, as there is absolutely
no need for them to continue suffering in silence."

The Recommendations note that many women may not report VA
symptoms to their doctor because of concerns about taking hormone
replacement therapy (HRT). Some of this reluctance is due to the
adverse publicity for HRT over recent years, but, regardless of
whether these concerns are justified, local oestrogen therapy for VA,
which delivers a low dose of hormone directly to the vagina, is not
associated with the possible risks of systemic (oral) HRT. Doctors
need to ensure patients fully understand this, so that they can
benefit from VA treatment.

In addition, women with VA may have cultural or religious reasons
for not talking to their doctor about their symptoms, and women in
general may be understandably reluctant to discuss such private
matters, particularly with a male doctor. The Recommendations offer
advice and guidance to healthcare professionals, to enable them to
initiate a successful dialogue with their patient. Most women express
relief and respond positively when a doctor initiates the
conversation about this topic.

Survey highlights challenges in awareness and communication about
VA

Results from the VIVA (Vaginal Health: Insights, Views &
Attitudes)[4] Survey, an international study involving over 3,500
postmenopausal women, show that 96% of postmenopausal women are
incorrectly attributing VA symptoms to other conditions such as
thrush or a bladder infection. The data also show that women do not
understand that VA is a chronic condition, and are resorting to
short-term symptom relief using lubricants and moisturisers, when
treatment for the underlying cause is available from the doctor.

The VIVA Survey also found that half of women would not discuss
VA symptoms with their physician. In addition, only two in five women
would talk to their spouse or partner about VA and two-thirds
reported that their mother never spoke to them about menopause,
suggesting that VA is still very much a taboo subject.

Dr Rossella Nappi, Associate Professor of Obstetrics and
Gynecology, Research Center for Reproductive Medicine and Director of
the Gynecological Endocrinology & Menopause Unit, University of Pavia
(Italy), said, "It is so sad that women are suffering in silence with
this condition; many believe that VA is just an inevitable part of
menopause and that they have no choice but to live with the
consequences. However, this is not the case, so it is vital that a
dialogue about vaginal health is initiated with postmenopausal
patients as part of routine."

The Recommendations for the management of postmenopausal vaginal
atrophy are published in the December 2010 edition of Climacteric,
and are available at http://www.imsociety.org. Patient education
materials are also available.

NOTES TO EDITORS

A webcast of the IMS press briefing for World Menopause Day will
be available from

Monday 11th October at http://www.imsociety.org.

About the IMS

The International Menopause Society (IMS) was established in 1978
and was the first menopause society in the world. At the time, it
signalled to the medical community that there was a need to address
specific gender-based and menopause-based issues, which until then
had not been regarded as important.

In the following years, many national and regional menopause
societies have been formed, but the IMS remains the only society with
a global responsibility and, as such, is a leading resource to which
the media as well as the medical professionals look for opinion and
guidance. This has been particularly important in recent years when
the merits of hormone therapy have come under intense debate.

About World Menopause Day

World Menopause Day on October 18th was initiated by the IMS, in
collaboration with the World Health Organization, as an opportunity
to alert the world to the importance of the menopause and the impact
that it has on the lives of so many women all around the world. In
observation of the Day, the IMS and the member national societies of
CAMS, the Council of Affiliated Menopause Societies, distribute
materials and organise activities to inform women about menopause,
its management and the impact of oestrogen loss.

About the VIVA (Vaginal Health: Insights, Views & Attitudes)
Survey

The VIVA survey was commissioned by Novo Nordisk and conducted by
Strategy One, an independent market research company. The survey was
conducted online in August 2010, with results received from 3,520
female respondents aged 55-65 years old from Great Britain, Sweden,
Denmark, Finland, Norway, Canada, and the United States of America.
The aim of the survey was to evaluate the attitudes of postmenopausal
women on the impact of Vaginal Atrophy (VA) and menopause on
different aspects of their lives and understand the barriers and
challenges to seeking advice and treatment.

---------------------------------

[1] Sturdee DW, Panay N. Recommendations for the management of
postmenopausal vaginal atrophy. Climacteric. 2010;13:

[2] Clinic: Vaginal Atrophy Definition. Available at:
http://www.mayoclinic.com/health/vaginal-atrophy/DS00770 Last
accessed July 2010

[3] Hextal A. Oestrogens and lower urinary tract function.
Maturitas 2000; 36: 83-92.

[4] Research conducted by an independent research agency in the
US, Canada, UK, Finland, Sweden, Denmark and Norway and is sponsored
by an unrestricted educational grant from Novo Nordisk.

ots Originaltext: The International Menopause Society (IMS)
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Media enquiries contact: Catherine Taman, Edelman,
T:+44(0)20-3047-2078, catherine.taman@edelman.com